| Title |
Advances in the Application and Impact of MicroRNAs as Therapies for Skin Disease
|
|---|---|
| Published in |
BioDrugs, September 2017
|
| DOI | 10.1007/s40259-017-0243-4 |
| Pubmed ID | |
| Authors |
Paul Lawrence, Joseph Ceccoli |
| Abstract |
The advent of RNA interference (RNAi) technology has profoundly impacted molecular biology research and medicine but has also advanced the field of skin care. Both effector molecules of RNAi, short-interfering RNA molecules and microRNAs (miRNAs), have been explored for their relative impact and utility for treating a variety of skin conditions. These post-transcriptional RNA regulatory molecules down-modulate protein expression through targeting of the 3' untranslated regions of messenger RNAs, leading to their degradation or repression through sequestration. As researchers hunt for genetic linkages to skin diseases, miRNA regulators have emerged as key players in the biology of keratinocytes, fibroblasts, melanocytes, and other cells of the skin. Herein, we attempt to coalesce the current efforts to combat various skin disorders and diseases through the development of miRNA-based technologies. |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 3 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Science communicators (journalists, bloggers, editors) | 2 | 67% |
| Members of the public | 1 | 33% |
Mendeley readers
The data shown below were compiled from readership statistics for 50 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 50 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 10 | 20% |
| Student > Master | 9 | 18% |
| Researcher | 6 | 12% |
| Other | 3 | 6% |
| Student > Postgraduate | 2 | 4% |
| Other | 5 | 10% |
| Unknown | 15 | 30% |
| Readers by discipline | Count | As % |
|---|---|---|
| Agricultural and Biological Sciences | 8 | 16% |
| Medicine and Dentistry | 7 | 14% |
| Biochemistry, Genetics and Molecular Biology | 7 | 14% |
| Immunology and Microbiology | 3 | 6% |
| Chemistry | 2 | 4% |
| Other | 6 | 12% |
| Unknown | 17 | 34% |
Attention Score in Context
This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 21 October 2019.
All research outputs
#6,351,041
of 23,001,641 outputs
Outputs from BioDrugs
#227
of 661 outputs
Outputs of similar age
#100,834
of 315,613 outputs
Outputs of similar age from BioDrugs
#1
of 6 outputs
Altmetric has tracked 23,001,641 research outputs across all sources so far. This one has received more attention than most of these and is in the 72nd percentile.
So far Altmetric has tracked 661 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.6. This one has gotten more attention than average, scoring higher than 65% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 315,613 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 67% of its contemporaries.
We're also able to compare this research output to 6 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them